24
Participants
Start Date
March 31, 2010
Primary Completion Date
January 31, 2012
Study Completion Date
January 31, 2012
Natalizumab
300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
Danish Multiple Sclerosis Center, Section 2082, Rigshospitalet, Copenhagen
Collaborators (1)
Copenhagen University Hospital, Hvidovre
OTHER
Biogen
INDUSTRY
University of Copenhagen
OTHER
Signifikans ApS
OTHER
Rigshospitalet, Denmark
OTHER